健康信念模型与家长对5-18岁儿童接种辉瑞-BioNTech和国药集团COVID-19疫苗的接受度:一项全国性调查
2022年3月一项全国在线横断面调查,采用多阶段随机抽样选取5-18岁儿童的家长,共1056名受访者。辉瑞-BioNTech疫苗接受率90%,国药集团疫苗接受率36%。多变量分析显示,感知益处和感知障碍与两种疫苗的接受度均相关。
要点
- 家长对辉瑞-BioNTech疫苗的接受率(90%)高于国药集团疫苗(36%)。
- 感知益处与辉瑞-BioNTech(aOR=25.30)和国药集团(aOR=17.94)疫苗接受度正相关。
- 感知障碍与辉瑞-BioNTech(aOR=0.06)和国药集团(aOR=0.20)疫苗接受度负相关。
核心结论
- 受访者对辉瑞-BioNTech疫苗的信心高于国药集团疫苗。
- 感知障碍和感知益处与受访者对两种疫苗的接受度均强相关。
- 在流行病和大流行期间,政府需要高效力和高安全性的疫苗以提高家长疫苗接受度的机会。
- 未来研究应探讨疫苗费用作为新上市自费疫苗的感知障碍。
研究设计与样本
- 2022年3月开展的一项横断面研究,使用在线调查。
- 受访者为公立和私立学校5-18岁儿童的家长。
- 采用多阶段随机抽样技术选择学校和受访者。
- 采用多变量分析检验疫苗接受度与健康信念模型(HBM)之间的关联。
主要发现
- 应答率为55%。
- 1056名受访者中,80.1%为女性,平均年龄41岁,95.8%不是卫生专业人员。
- 辉瑞-BioNTech疫苗接受率高于国药集团疫苗(90% vs 36%)。
- 多变量分析显示,感知益处与辉瑞-BioNTech疫苗接受度相关(aOR=25.30,95%CI=10.02-63.89),与国药集团疫苗接受度相关(aOR=17.94,95%CI=9.56-33.66)。
- 感知障碍与辉瑞-BioNTech疫苗接受度相关(aOR=0.06,95%CI=0.01-0.50),与国药集团疫苗接受度相关(aOR=0.20,95%CI=0.11-0.40)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究应探讨疫苗费用作为新上市自费疫苗的感知障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During the COVID-19 pandemic, several vaccines received approval for children aged 18 or younger. Parents' decisions to accept vaccines play an important role in the success of vaccination campaigns. The Health Belief Model (HBM) may explain its association with vaccine acceptance. This study examined parents' Pfizer-BioNTech and Sinopharm vaccine acceptance for their children and its association with HBM. METHODS: A cross-sectional study was conducted in March 2022 using an online survey. Respondents were parents of children aged 5-18 in public and private schools. The multistage random sampling technique was used to choose schools and respondents. Multivariable analysis was conducted to examine the association between vaccine acceptance and HBM. RESULTS: The response rate was 55 %. Of 1,056 respondents, 80.1 % were female, with a mean age of 41, and 95.8 % were not health professionals. Pfizer-BioNTech had a greater acceptance rate than Sinopharm (90 % v.s. 36 %). The Multivariable analysis shows that perceived benefits (aOR = 25.30, 95 %CI = 10.02-63.89 and aOR = 17.94, 95 %CI = 9.56-33.66 for Pfizer-BioNTech and Sinopharm, respectively) and perceived barriers (aOR = 0.06, 95 %CI = 0.01-0.50 and aOR = 0.20, 95 %CI = 0.11-0.40 for Pfizer-BioNTech and Sinopharm, respectively) were associated with vaccine acceptance for both vaccines. Education was associated with Pfizer-BioNTech vaccine acceptance (aOR = 0.96, 95 %CI 0.71-1.29). CONCLUSIONS: The respondents were more confident in Pfizer-BioNTech than Sinopharm. Perceived barriers and perceived benefits were strongly associated with the respondents' vaccine acceptance for both vaccines. During epidemics and pandemics, the government needs vaccines with high efficacy and safety for a higher chance of parents' vaccine acceptance. Future research should examine vaccine costs as perceived barriers for a newly out-of-pocket developed vaccine.
引用
- Vatcharavongvan P, Boonyanitchayakul N, Khampachuea P, et al. Health Belief Model and parents' acceptance of the Pfizer-BioNTech and Sinopharm COVID-19 vaccine for children aged 5-18 years Old: A national survey. Vaccine. 2023. PMID: 36707336. doi:10.1016/j.vaccine.2023.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。